Systemic lupus erythematosus laboratory tests: Difference between revisions
Line 5: | Line 5: | ||
== Overview == | == Overview == | ||
Laboratory findings consistent with the diagnosis of systemic lupus erythematosus include [[autoantibodies]] elevation of [[ANA]], [[anti-dsDNA antibody]], [[anti-SM antibody]] and [[antiphospholipid antibodies]], and decrease of [[complement]] levels. | Laboratory findings consistent with the diagnosis of systemic lupus erythematosus include [[autoantibodies]] elevation of [[ANA]], [[anti-dsDNA antibody]], [[anti-SM antibody]] and [[antiphospholipid antibodies]], and decrease of [[complement]] levels. Non specific laboratory findings include mild [[pancytopenia]], elevated levels of [[creatinine]] and [[proteinuria]] due to [[renal failure]] (secondary to [[nephritis]]), elevated levels of [[ESR]] and [[C-reactive protein|CRP]] as [[Acute phase reactant|acute phase reactants]], and positive [[Coombs test|direct coombs test]]. | ||
== Laboratory tests == | == Laboratory tests == | ||
Line 17: | Line 17: | ||
!result | !result | ||
!clinical correlation | !clinical correlation | ||
|- | |- | ||
| rowspan="4" |Hematology | | rowspan="4" |Hematology | ||
Line 26: | Line 25: | ||
* Mild [[anemia]] | * Mild [[anemia]] | ||
* [[Thrombocytopenia]] | * [[Thrombocytopenia]] | ||
| | |||
* Non-specific | * Non-specific | ||
* May be related to constitutional symptoms | * May be related to constitutional symptoms | ||
Line 32: | Line 31: | ||
|[[Serum creatinine]] | |[[Serum creatinine]] | ||
|Elevated | |Elevated | ||
| | |||
* Suggestive of [[renal dysfunction]] | * Suggestive of [[renal dysfunction]] | ||
|- | |- | ||
Line 39: | Line 38: | ||
| rowspan="2" | | | rowspan="2" | | ||
* Acute [[pancreatitis]] | * Acute [[pancreatitis]] | ||
|- | |- | ||
|[[Lipase]] | |[[Lipase]] | ||
|- | |- | ||
| rowspan="2" |Urine | | rowspan="2" |Urine | ||
Line 52: | Line 49: | ||
* [[Proteinuria]] | * [[Proteinuria]] | ||
* Cellular casts | * Cellular casts | ||
| | | rowspan="2" | | ||
* Suggestive of [[renal dysfunction]] | * Suggestive of [[renal dysfunction]] | ||
|- | |- | ||
Line 60: | Line 57: | ||
|[[ANA]] | |[[ANA]] | ||
|Elevated | |Elevated | ||
| | |||
* Positive in virtually all patients with SLE at some time in the course of their disease | * Positive in virtually all patients with SLE at some time in the course of their disease | ||
|- | |- | ||
Line 68: | Line 65: | ||
* [[IgG]] and [[IgM]] [[Anti-cardiolipin antibodies|anticardiolipin [aCL] antibodies]] | * [[IgG]] and [[IgM]] [[Anti-cardiolipin antibodies|anticardiolipin [aCL] antibodies]] | ||
* [[IgG]] and [[IgM]] anti-beta2-glycoprotein [GP] | * [[IgG]] and [[IgM]] anti-beta2-glycoprotein [GP] | ||
| | |||
* Can be predictive of [[hematologic]] and [[Thromboembolic disease|thromboembolic]] involvement | * Can be predictive of [[hematologic]] and [[Thromboembolic disease|thromboembolic]] involvement | ||
|- | |- | ||
Line 76: | Line 73: | ||
* C4: reduced | * C4: reduced | ||
* CH50: reduced | * CH50: reduced | ||
| | |||
* Impaired clearance of [[immune complexes]] | * Impaired clearance of [[immune complexes]] | ||
* Partial [[complement]] deficiency during disease flare ups | * Partial [[complement]] deficiency during disease flare ups | ||
Line 84: | Line 81: | ||
|[[Erythrocyte sedimentation rate|Erythrocyte sedimentation rate (ESR)]] | |[[Erythrocyte sedimentation rate|Erythrocyte sedimentation rate (ESR)]] | ||
|Elevated | |Elevated | ||
| | |||
* Non-specific | * Non-specific | ||
|- | |- | ||
|[[C-reactive protein|C-reactive protein (CRP)]] | |[[C-reactive protein|C-reactive protein (CRP)]] | ||
|Elevated | |Elevated | ||
| | |||
* Non-specific | * Non-specific | ||
|- | |- | ||
|Urine protein-to-creatinine ratio | |Urine protein-to-creatinine ratio | ||
|Elevated | |Elevated | ||
| | |||
* [[Lupus nephritis]] | * [[Lupus nephritis]] | ||
|- | |- | ||
|[[Anti-dsDNA antibody]] | |[[Anti-dsDNA antibody]] | ||
|Elevated | |Elevated | ||
| | |||
* Highly specific for SLE | * Highly specific for SLE | ||
* In 70% of patients | * In 70% of patients | ||
Line 105: | Line 102: | ||
|[[Anti-SM antibody|Anti-SM antibodies]] | |[[Anti-SM antibody|Anti-SM antibodies]] | ||
|Elevated | |Elevated | ||
| | |||
* Highly specific for SLE | * Highly specific for SLE | ||
* In 30% of patients | * In 30% of patients | ||
Line 113: | Line 110: | ||
|Anti-Ro/SSA antibodies<ref name="pmid15593352">{{cite journal |vauthors=Benito-Garcia E, Schur PH, Lahita R |title=Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests |journal=Arthritis Rheum. |volume=51 |issue=6 |pages=1030–44 |year=2004 |pmid=15593352 |doi=10.1002/art.20836 |url=}}</ref> | |Anti-Ro/SSA antibodies<ref name="pmid15593352">{{cite journal |vauthors=Benito-Garcia E, Schur PH, Lahita R |title=Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests |journal=Arthritis Rheum. |volume=51 |issue=6 |pages=1030–44 |year=2004 |pmid=15593352 |doi=10.1002/art.20836 |url=}}</ref> | ||
|Elevated | |Elevated | ||
| | |||
* In 30% of patients | * In 30% of patients | ||
* More commonly associated with [[Sjögren’s syndrome]] | * More commonly associated with [[Sjögren’s syndrome]] | ||
Line 119: | Line 116: | ||
|Anti-La/SSB antibodies<ref name="pmid15593352">{{cite journal |vauthors=Benito-Garcia E, Schur PH, Lahita R |title=Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests |journal=Arthritis Rheum. |volume=51 |issue=6 |pages=1030–44 |year=2004 |pmid=15593352 |doi=10.1002/art.20836 |url=}}</ref> | |Anti-La/SSB antibodies<ref name="pmid15593352">{{cite journal |vauthors=Benito-Garcia E, Schur PH, Lahita R |title=Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests |journal=Arthritis Rheum. |volume=51 |issue=6 |pages=1030–44 |year=2004 |pmid=15593352 |doi=10.1002/art.20836 |url=}}</ref> | ||
|Elevated | |Elevated | ||
| | |||
* In 20% of patients | * In 20% of patients | ||
* More commonly associated with [[Sjögren's syndrome|Sjögren’s syndrome]] | * More commonly associated with [[Sjögren's syndrome|Sjögren’s syndrome]] | ||
Line 125: | Line 122: | ||
|Anti-U1 RNP antibodies<ref name="pmid15593352">{{cite journal |vauthors=Benito-Garcia E, Schur PH, Lahita R |title=Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests |journal=Arthritis Rheum. |volume=51 |issue=6 |pages=1030–44 |year=2004 |pmid=15593352 |doi=10.1002/art.20836 |url=}}</ref> | |Anti-U1 RNP antibodies<ref name="pmid15593352">{{cite journal |vauthors=Benito-Garcia E, Schur PH, Lahita R |title=Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests |journal=Arthritis Rheum. |volume=51 |issue=6 |pages=1030–44 |year=2004 |pmid=15593352 |doi=10.1002/art.20836 |url=}}</ref> | ||
|Elevated | |Elevated | ||
| | |||
* In approximately 25 percent of patients with SLE | * In approximately 25 percent of patients with SLE | ||
* Not specific, always present in patients with [[mixed connective tissue disease]] (MCTD) | * Not specific, always present in patients with [[mixed connective tissue disease]] (MCTD) | ||
Line 131: | Line 128: | ||
|Antiribosomal P protein antibodies | |Antiribosomal P protein antibodies | ||
|Elevated | |Elevated | ||
| | |||
* High specificity for SLE & low sensitivity for SLE | * High specificity for SLE & low sensitivity for SLE | ||
* Lack specificity for involvement of a particular organ system or disease manifestation | * Lack specificity for involvement of a particular organ system or disease manifestation | ||
Line 140: | Line 137: | ||
| | | | ||
* Clinically important in the absence of other causes of hemolytic anemia | * Clinically important in the absence of other causes of hemolytic anemia | ||
|} | |} | ||
Revision as of 14:49, 27 July 2017
Systemic lupus erythematosus Microchapters |
Differentiating Systemic lupus erythematosus from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Systemic lupus erythematosus laboratory tests On the Web |
American Roentgen Ray Society Images of Systemic lupus erythematosus laboratory tests |
Directions to Hospitals Treating Systemic lupus erythematosus |
Risk calculators and risk factors for Systemic lupus erythematosus laboratory tests |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]
Overview
Laboratory findings consistent with the diagnosis of systemic lupus erythematosus include autoantibodies elevation of ANA, anti-dsDNA antibody, anti-SM antibody and antiphospholipid antibodies, and decrease of complement levels. Non specific laboratory findings include mild pancytopenia, elevated levels of creatinine and proteinuria due to renal failure (secondary to nephritis), elevated levels of ESR and CRP as acute phase reactants, and positive direct coombs test.
Laboratory tests
Laboratory findings consistent with the diagnosis of systemic lupus erythematosus include autoantibodies elevation of ANA, anti-dsDNA antibody, anti-SM antibody and antiphospholipid antibodies, and decrease of complement levels.[1][2][3][4]
General laboratory changes during SLE flares
Lab exam | result | clinical correlation | |
---|---|---|---|
Hematology | Complete blood count |
| |
Serum creatinine | Elevated |
| |
Amylase | Elevated |
| |
Lipase | |||
Urine | Urinalysis |
|
|
Urine sediment | |||
Serology | ANA | Elevated |
|
Antiphospholipid antibodies[5] |
|
| |
Complement levels[6] |
|
| |
Erythrocyte sedimentation rate (ESR) | Elevated |
| |
C-reactive protein (CRP) | Elevated |
| |
Urine protein-to-creatinine ratio | Elevated | ||
Anti-dsDNA antibody | Elevated |
| |
Anti-SM antibodies | Elevated |
| |
Anti-Ro/SSA antibodies[7] | Elevated |
| |
Anti-La/SSB antibodies[7] | Elevated |
| |
Anti-U1 RNP antibodies[7] | Elevated |
| |
Antiribosomal P protein antibodies | Elevated |
| |
Direct Coombs' test | Positive |
|
If the initial ANA test is negative, but the clinical suspicion of SLE is high, then additional antibody testing may still be appropriate. This is partly related to the differences in the sensitivity and specificity among the methods used to detect ANA.
Laboratory exams to distinguish SLE from other diseases
Test | Interpretation |
---|---|
Anti-cyclic citrullinated peptide (CCP) antibodies |
|
Rheumatoid factor (RF) | |
Serological studies for infection |
|
| |
| |
| |
Creatine kinase (CK) |
A more detailed look into auto-antibodies in SLE
Antibodies | Prevalence | Association with disease activity | Pathogenesis involvement |
---|---|---|---|
ANA | 80 | - | Cutaneous lupus erythematosus |
dsDNA | 70 | -/+ | Lupus nephritis |
Anti-Sm antibodies | 30 | - | Renal, neurologic, vasculitis and hematologic diseases |
snRNP (U1 RNP) | 30-40 | - | - |
SSA/Ro | 30 | - | Neonatal lupus |
SSB/La | 20 | - | Neonatal lupus |
Antiribosomal P protein antibodies | 20 | - | Neuro-psychiatric disease, liver disease |
RF | 20 | - | - |
References
- ↑ Tan EM (1989). "Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology". Adv. Immunol. 44: 93–151. PMID 2646863.
- ↑ Willitzki A, Hiemann R, Peters V, Sack U, Schierack P, Rödiger S, Anderer U, Conrad K, Bogdanos DP, Reinhold D, Roggenbuck D (2012). "New platform technology for comprehensive serological diagnostics of autoimmune diseases". Clin. Dev. Immunol. 2012: 284740. doi:10.1155/2012/284740. PMC 3536031. PMID 23316252.
- ↑ Li J, Leng X, Li Z, Ye Z, Li C, Li X, Zhu P, Wang Z, Zheng Y, Li X, Zhang M, Tian XP, Li M, Zhao J, Zhang FC, Zhao Y, Zeng X (2014). "Chinese SLE treatment and research group registry: III. association of autoantibodies with clinical manifestations in Chinese patients with systemic lupus erythematosus". J Immunol Res. 2014: 809389. doi:10.1155/2014/809389. PMC 4017718. PMID 24864270.
- ↑ Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O, Komisar O, Slonimsky E, Klang E, Lotan E, Welt M, Marai I, Shina A, Amital H, Shoenfeld Y (2015). "A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients". Autoimmun Rev. 14 (1): 75–9. doi:10.1016/j.autrev.2014.10.003. PMID 25449682.
- ↑ Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006). "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)". J. Thromb. Haemost. 4 (2): 295–306. doi:10.1111/j.1538-7836.2006.01753.x. PMID 16420554.
- ↑ Truedsson L, Bengtsson AA, Sturfelt G (2007). "Complement deficiencies and systemic lupus erythematosus". Autoimmunity. 40 (8): 560–6. doi:10.1080/08916930701510673. PMID 18075790.
- ↑ 7.0 7.1 7.2 Benito-Garcia E, Schur PH, Lahita R (2004). "Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests". Arthritis Rheum. 51 (6): 1030–44. doi:10.1002/art.20836. PMID 15593352.